screen_shot_2015-02-19_at_07

Pharming names new chief scientific officer

pharmafile | February 19, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pharming, perry calais 

Dutch biopharma development firm Pharming has named Dr Perry Calias as the company’s chief scientific officer. 

Calias will have overall responsibility for the firm’s Enzyme Replacement Therapy programmes, and will oversee new product development and strategic direction for the company. 

Pharming also plans to open a small US R&D office in Boston, and Calias will be based there and is to split his time between Boston, Paris and Leiden. 

Advertisement

Calias is a specialist in developing targeted therapies, and worked as a senior director for Shire within its Human Genetic Therapeutics division.

Calias has held various R&D positions at BBB Technologies, EyeGate Pharmaceuticals, Eyetech Pharmaceuticals, Draper Laboratories and Genzyme. 

Related Content

Pharming forges production deal with Sanofi Chimie

Dutch biotechnology group Pharming has signed a toll manufacturing agreement with Sanofi Chimie in order …

Pharming’s orphan drug receives second setback in Europe

Dutch biotech company Pharming has suffered a blow, after its lead product Rhucin was rejected …

The Gateway to Local Adoption Series

Latest content